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ABSTRACT 
Objective: A simple, sensitive, precise and accurate stability-indicating HPLC method has been developed and validated for determination of 
Azathioprine in bulk drug and in pharmaceutical dosage form in the presence of degradation products.  
Methods: An isocratic, reversed phase HPLC method was developed to separate the drug from the degradation products, using a Hypersil C
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, 150 X 
4.6 mm, 5µ, Thermostat column compartment connected with Waters (alliance) Empower software. Mobile phase consists mixture of Potassium 
dihydrogen phosphate(A) and Acetonitrile(B) in the ratio (pH 6.50±0.1, ratio 60:40 v/v) at a flow rate of 1.0 mL /min. The linear regression analysis 
data for the calibration curve showed a good linear relationship with regression coefficient 1. The detection was carried out at a wavelength of 254 
nm.  
Results: The linearity of the method were excellent over the range 2.5-15 μg/ml, the linear regression equation was Y=76621×+12515. The 
Azathioprine was subjected to stress conditions of hydrolysis (acid, base), photolysis and thermal degradation. Degradation was observed for 
Azathioprine in acid, base, heat and UV. The degradation products were well resolved from the main peak. The percentage recovery of Azathioprine 
was from (98.0 to 102.0 %.) in the pharmaceutical dosage form. 
Conclusion: The results demonstrated that the method would have a great value when applied in quality control and stability studies. The 
developed method was validated with respect to linearity, accuracy (recovery), precision, system suitability, specificity and robustness. The forced 
degradation studies prove the stability indicating power of the method. 
 
INTRODUCTION 
Azathioprine is an immunosuppressive drug used in organ 
transplantation and autoimmune diseases and belongs to the 
chemical class of purine analogues.[ 1 ] Synthesized originally as a 
cancer drug and a prodrug formercaptopurine in 1957, it has been 
widely used as an immunosuppressant for more than 50 years.[2] 
Azathioprine acts as a pro drug for mercaptopurine, inhibiting 
an enzyme that is required for the synthesis of DNA. Thus it most 
strongly affects proliferating cells, such as the T cells and B cells of 
the immune system.[3]Azathioprine, is chemically 6-(1-methyl-4-
nitroimidazole-5-yl) thiopurine (Figure- 1), is an 
immunosuppressive agent. They are used in the chemotherapy of 
acute leukemia, for immunosuppressant after solid-organ 
transplantation, and increasingly for immunomodulation in 
autoimmune disease. Currently, AZA is standard treatment in 
patients with chronically active inflammatory bowel disease (IBD). 
Azathioprine acts on several modes in cellular immunity processes. 
It inhibits lymphocyte activation, lymphocyte differentiation, in vitro 
lymphocyte stimulation, and in vitromixed lymphocyte reaction and 
it reduces the activity of natural killer lymphocytes.[4, 5] It is also 
used in systemic anti-inflammatory states, such as rheumatoid 
arthritis, lupuserythematosus, colitis ulcerosa, auto immunological 
hepatitis and Crohn’s disease [6]. And immunosuppressive action, 
and is given orally or by intravenous (IV) route [7]. A validated UPLC 
method for the determination of process-related impurities in 
Azathioprine bulk drug [8]. In the United State Pharmacopoeia 
monograph of Azathioprine API, thin layer chromatographic test is 
described for 6-mercaptopurine [9]. 
Administration of Azathioprine in transplant patients leads rapidly 
to severe my-elosuppression when the homozygote allele for 
TPMTdeficiency is expressed [15]. Then, high 6-TGN concentrations 
in RBCs could be correlated with low erythrocyteTPMT activity, 
which exhibits a favorable clinical out-come in children with acute 
lymphoblastic leukemia treated by6-MP [16]. However, the relation 
between high 6-TGN concentrations in RBCs and 
myelosuppressioninduced by Azathioprine remains controversial 
[17]. More recently, Me6-TIMP was shown to strongly in-hibit 
purine de novo synthesis in a concentration-depen-dent manner, 
leading to cytotoxicity in Molt F4 cells, suggesting that methyl 6-
mercaptopurine nucleotides (Me6-MPNs) could explain part of the 
pharmacologic activity of azathioprine [18]. A few analytical 
methods LC-MS, GC-MS were reported in literature and estimated 
the drug levels in blood plasma [11, 12]. Azathioprine and the 
metabolite 6-MP are moderately bound to serum proteins (30%). 
Azathioprine and 6-MP are structurally very similar, differing only in 
that azathioprine has a methyl–nitro-imidazolyl group attached to 
the sulfur atom at the 6-position of the purine ring of 6-MP [30]. On 
the average, 47% of an orally administered dose of azathioprine is 
available to the systemic circulation. A number of analytical methods 
have been used to determine the azathioprine with 6-
mercaptopurine. It involves mainly high performance liquid 
chromatography [31]. And very few liquid chromatography tandem 
mass spectrometry methods [32]. Have been developed for the 
quantification in biological samples of plasma [33, 34&35].  
 
 
Fig. 1: Chemical structure of Azathioprine 
 
The author has developed RP-HPLC method based on the use of 
symmetry column, without use of an internal standard. An attempt has 
been made to develop and validate all methods to ensure their 
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accuracy, precision, repeatability, reproducibility and other analytical 
method validation parameters as mentioned in the various guidelines. 
The Chemical Structure of Azathioprine in figure.1.  
However, in the knowledge authors, no account has been reported 
for stability indicating assay method for determination of 
Azathioprine. According to current good manufacturing practices, all 
drugs must be tested with a stability-indicating assay method before 
release. Till date, no stability-indicating HPLC assay method for the 
determination of azathioprine is available in the literature. It was 
felt necessary to develop a stability indicating liquid 
chromatography (LC) method for the determination of Azathioprine 
as bulk drug and pharmaceutical dosage form and separate the 
drugs from the degradation products under the International 
Conference on Harmonization (ICH) suggested conditions 
(hydrolysis, photolysis and thermal stress) [36&37]. Therefore, the 
aim of the present study was to develop and validate a stability-
indicating HPLC assay method for azathioprine as bulk drug and in 
pharmaceutical dosage form as per ICH guidelines [37]. 
MATERIALS AND METHODS 
Material and reagents 
Azathioprine bulk drug (purity 99.7) and tablet Azathioprine (100 
mg) were obtained from Life Care labs, ameerpet (Hyderabad, 
India). Hydrochloric acid, sodium hydroxide pellets, dihydrogen 
phosphates and Acetonitrile from were obtained Bross Scientifics 
Laboratories Tirupati, AP India. All chemicals used are of HPLC 
grade. Milli-QWaterwas used throughout the experiment. 
Instrumentation 
Waters HPLC 2 2695 series consisting pump, Auto Sampler, UV-Vis 
detector, Thermostat column compartment connected with 
Waters(alliance) Empower software Hypersil C8
HPLC method development parameters 
, 150 X 4.6 mm, 5µ, 
Thermostat column compartment connected with Waters(alliance) 
Empower software. At a flow rate of 1.0 mL/ min. The injection 
volume was 20 μL. The detection wavelength was 254 nm. 
 
Chromatographic conditions 
Column  C8, 150 X 4.6 mm, 5µ 
Flow rate   1.0 mL / min 
Wavelength  254 nm 
Column temperature  30°C 
Injection volume  20 µL 
Run time  10 minutes 
Diluents  Mobile phase 
Elution  Isocratic 
 
Preparation of solutions 
Mobile phase preparation  
2.72 gms of Potassium dihydrogen phosphate in 1 Ltr water, Adjust 
pH 6.50±0.1 with dilute potassium hydroxide solution: Acetonitrile 
in the ratio 60: 40. The mobile phase was premixed and filtered 
through a 0.45μ nylon filter and degassed. 
Preparation of stock and standard solutions 
All solutions were prepared on a weight basis and solution 
concentrations were also measured on weight basis to avoid the 
use of an internal standard. Standard solution of azathioprine was 
prepared by dissolving the drug in the diluents and diluting them 
to the desired concentration. Diluents were composed of 
Potassium dihydrogen phosphate and Acetonitrile in the ratio (60: 
40 v/v). Approximately 50 mg of azathioprine was accurately 
weighed, transferred in a 100 mL volumetric flask, add 30 mL of 
diluents and sonicate to dissolve and dilute to volume with 
diluent. Transfer 10 mL of standard stock solution into 100 mL 
volumetric flask and dilute to volume with diluent. And an 
appropriate concentration of sample (20 μgmL-1 assay 
concentration) was prepared at the time of analysis. 
Sample solution (tablets) 
Crush to powder 20 tablets of azathioprine weigh and transfer the 
tablet powder equal to 50 mg of azathioprine into 100 mL 
volumetric flask add 30 mL of diluent, sonicate to dissolve for 10 
minutes and dilute to volume with diluent. Further filtrate the 
solution through 0.45µ filter. And an appropriate concentration of 
sample (20 μgmL-1 assay concentration) was prepared at the time of 
analysis. Inject 20 µL of blank solution, placebo solution, three times 
of Standard solution, Disregard peaks due to blank and placebo. 
Assay 
Diluted to 10 ml of standard stock solution, into 100 mL and make 
up to volume with diluent. 
Repeated same procedure for remaining three preparations 
Sample Preparation 
Crush to powder 20 tablets, weigh and transfer the tablet powder 
equal to 50 mg of  
AZT into 100 mL volumetric flask added 30 mL of diluent, sonicate 
to dissolve for 10 minutes and dilute to volume with diluent. Further 
filtrate the solution through 0.45µ 
Filter. Procedure: Inject 20 µL of blank solution, placebo solution, 
three times of Standard solution, Disregard peaks due to blank and 
placebo. 
System suitability requirements from SST solution 
a) Tailing factor: NMT 2.0 
b) Theoretical Plates: NLT 2000 
Procedure for forced degradation study 
Stability testing is an important part of the process of drug product 
development. The purpose of stability testing is to provide evidence 
of how the quality of a drug substance or drug product varies with 
time under a variety of environmental conditions, for example 
temperature, humidity, and light and enables recommendation of 
storage conditions, retest periods, and shelf life to be established. 
The two main aspects of drug product that plays an important role 
in shelf-life determination are assay of the active drug and the 
degradation products generated during stability studies. 
Acidic degradation 
5 mg drug were dissolved in the diluents A&B. Forcibly degrade the 
sample by using 0.1 N HCl at room temperature. Collect 10 mL of the 
sample upto 48 hours.  
Alkaline degradation  
5 mg drug were dissolved in the diluents A&B. Forcibly degrade the 
sample by using 0.1 N NaOH at room temperature. Initially collect 10 
mL of the sample upto 48 hours. 
Thermal degradation  
10 mg drug were forcibly degrading the sample exposed to heat 
under oven at 75°C of temperature. Then the working solution was 
prepared using diluents A&B. Collect the sample after 10th
Specificity is the ability of the method to assess unequivocally the 
analyte in the presence of components, which may be expected to be 
present. Typically, these might include degradation products, matrix 
the specificity of the developed HPLC method for azathioprine was 
carried out in the presence of its degradation products. Stress 
studies were performed for azathioprine in bulk drug to provide an 
 day. 
Photo degradation  
10 mg of drug is exposed to the short wavelength (254 nm) UV light 
for 48 h. Then the working solution was prepared using diluents 
A&B forcibly degrades the sample under UV.  
Method Validation 
Specificity 
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indication of the stability indicating property and specificity of the 
proposed method. Intentional degradation was attempted to stress 
conditions exposing it with acid (01N hydrochloric acid), alkali (0.1N 
NaOH), heat (750
The limit of detection (LOD) and limit of quantification (LOQ) were 
determined by calibration curve method. Specific calibration curve 
was constructed using samples containing the analytes in the range 
of LOD and LOQ. The LOD and LOQ for azathioprine in LC were 
1.95and 3.62 μg mL
C) and UV light (254 nm wavelength) to evaluate 
the ability of the proposed method to separate azathioprine from its 
degradation products. For light and heat study, the study period was 
48 h whereas for acid and base 48 h. Peak purity test for 
azathioprine was by using PDA detector in stress samples. 
Precision 
Assay of method precision (intra-day precision) was evaluated by 
carrying out six independent assays of azathioprine test samples 
against reference standard; the percentage of RSD of six assay values 
obtained was calculated. The intermediate precision (inter-day 
precision) of the method was also evaluated using two different 
analysts, different HPLC systems and different days in the same 
laboratory the results were tabled in Table- 3. 
Accuracy (recovery test) 
Accuracy of the method was studied by recovery experiments. The 
recovery experiments were performed by adding known amounts of 
the drugs in the placebo. The recovery was performed at three 
levels, 50, 100 and 150% of the label claim of the tablet (50 mg of 
azathioprine). The recovery samples were prepared in the 
aforementioned procedure, and then 10 mL of azathioprine solution 
were transferred into a 50 mL volumetric flask and diluted to 
volume with diluent B. Three samples were prepared for each 
recovery level. The Solutions were then analyzed, and the 
percentage recoveries were calculated from the calibration curve. 
The recovery values for azathioprine ranged from 98.0 to 102.0%. 
The average recoveries of three levels for azathioprine was 99.86% 
the results were tabled in Table- 2. 
Linearity 
The linearity of the response of the drug was verified at six 
concentration levels, ranging from 25 to 150% of the targeted level 
(20 μg mL-1). Concentration standard solutions containing 2.5-15 μg 
mL-1 of azathioprine in each linearity level were prepared. Linearity 
solutions were injected in triplicate. The calibration graphs were 
obtained by plotting peak area versus the concentration data and 
were treated by least-squares linear regression analysis. The 
equation of the calibration curve for azathioprine obtained 
Y=76621×+12515, the Calibration graphs were found to be linear in 
the aforementioned concentrations. The correlation coefficient of 
determination is 1. The linearity calibration curve was showed in 
figure-8. The results were tabulated in table-4. The sample 
Chromatogram showed in Figure-3and the Overlaid Linearity 
Chromatogram showed in Figure- 2. 
Limit of detection and limit of quantification (LOD and LOQ) 
-1
Robustness 
To determine the robustness of the developed method experimental 
conditions were purposely altered and the resolution between 
azathioprine and acid degradation products were evaluated. The 
flow rate of the mobile phase was 1.0 mL min± 0.1 ml, and temp 
variation ± 5
, respectively. LOD and LOQ were calculated 
by using the following equations. LOD = 3.3Sa/b, LOQ = 10Sa/b. 
where Sa is the standard deviation of the calibration curve and b is 
the slope of the calibration curve. Precision at limit of 
quantification and limit of detection was checked by analyzing six 
test solutions prepared at LOQ and LOD levels and calculating the 
percentage RSD of area. 
oC to study the effect of flow rate on the resolution. The 
effect of percent organic strength on resolution was studied by 
varying. Acetonitrile from –10to+10%. The resolution in the 
robustness study was not less than <2.0 in all conditions. The 
stability of the standard solutions and the sample solutions was 
tested at intervals of 48hours and 10th day. The stability of solutions 
was determined by comparing results of the assay of the freshly 
prepared standard solutions. The RSD for the assay results 
determined up to 10th day for azathioprine was 0.53%. The assay 
values were within 1.5% after 10th day. The results indicate that the 
solutions were stable for 10th day at ambient temperature. 
Ruggedness 
The ruggedness of test method was demonstrated by carrying out 
precision study in six preparations of sample on a single batch 
sample by different analysts, the results of the intermediate 
precision study are tabulated as below table-3. The mean % RSD for 
both method precision and intermediate precision < 2.0. 
RESULTS AND DISCUSSION 
Optimization of chromatographic conditions 
The primary target in developing this stability indicating HPLC 
method is to achieve the resolution between azathioprine and its 
degradation products. To achieve the separation of degradation 
products we used stationary phase C-8 and combination of mobile 
phase consist of Potassium dihydrogen phosphate: Acetonitrile in 
the ratio (60:40 v/v), The separation of the degradation product and 
azathioprine was achieved on Hypersil C8 stationary phase and the 
combination of mobile phase consist of Potassium dihydrogen 
phosphate: Acetonitrile in the ratio (60:40 v/v), The tailing factor 
obtained was less than two and retention time was about 3.674 min 
for the main peak and less than 4 min for the degradation products, 
which would reduce the total run time and ultimately increase the 
productivity thus reducing the cost of analysis per sample. Forced 
degradation study showed the method is highly specific and entire 
degradation products were well resolved from the main peak. The 
developed method was found to be specific and method was 
validated as per ICH guidelines. 
Result of forced degradation experiments 
Degradation was observed for azathioprine samples during stress 
conditions like heat, UV light, base and acid. Azathioprine was 
degraded into acid (Figure 4), base (Figure5), Heat (Figure 6) and 
UV (Figure 7) forms polar impurities. In the acidic condition 7.5%, in 
the basic condition 4.78% after 48 h, in the heat condition 7.46 % 
and in the UV condition 7.93 % after 10th
The contents of drug in tablets were determined by the proposed 
method using the calibration Curve. 
 
Table 1: Summary of forced degradation results for Azathioprine 
 day. Degradation was 
observed for azathioprine. Peak purity results greater than 990 
indicate that the azathioprine peak is homogeneous in all stress 
conditions tested. The unaffected assay of azathioprine in the tablets 
confirms the stability indicating power of the method the summary 
of forced degradation results were tabled in Table -1. 
Determination of active ingredients in tablets 
Stress conditions  Time / h  Peak Area Assay of active Degradation/ (%)  
Substance 
Peak purity 
Acid hydrolysis  48  3558178  92.5  7.5  0.999  
Base hydrolysis  48  3659926  95.22  4.78  1.0  
Heat  75o  3557060 C  92.54  7.46  0.999  
UV  10th  3538833  Day  92.07  7.93  1.0 
Peak purity values in the range of 0.999 -1000 indicate the homogenous peak 
Naidu et al. 





Fig. 2: Overlaid Linearity Chromatogram of Azathioprine 
 
 
Fig. 3: Sample Chromatogram of 25 μg/mL of standard solution of Azathioprine 
 
S. No. Peak Name RT Area Height % Area USP Tailing USP Plate Count 
1 Azathioprine 3.674 959197 132877 100.000 1.13 5924.98 
 
 
Fig. 4: Chromatogram of Azathioprine in acid degradation, in 0.1NHCl 
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Fig. 5: Chromatogram of Azathioprine in Base degradation; in 0.1N NaOH 
 
 




Fig. 7: Chromatogram of Azathioprine in UV degradation in 10th Day 
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Fig. 8: Linearity of Azathioprine 
 
Table 2: Results of recovery tests of Azathioprine 
Level of addition / (%) Amount added / μg Recovery / (%) Average recovery / (%) 
50 25 100.25   99.86 
100 50 99.87 
150 75 99.46 
 
Table 3: Result of precision of the Azathioprine test method 
Analyst 1 (intra-day precision) Analyst 2 (inter-day precision) 
S No Name RT Area Name RT Area 
1 Injection-1  3.68  3784665 Injection-1 3.678 3840547 
2 Injection-2 3.681 3788099 Injection-2 3.679 3843549 
3 Injection-3 3.681 3794539 Injection-3 3.682 3848905 
4 Injection-4 3.685 3820154 Injection-4 3.686 3855487 
5 Injection-5 3.689 3833276 Injection-5 3.683 3852038 
6 Injection-6 3.691 3840598 Injection-6 3.685 3859904 
 AVG 3.685 3810222 AVG 3.682 3850072 
STDEV 0.005 24254.4 STDEV 0.003 7273.1 
%RSD 0.126 0.64 %RSD 0.087 0.189 
 
Table 4:  Linearity of Azathioprine 
Linear solutions % Conc. Area 
25 12.5000 959197 
50 25.0000 1931934 
75 37.5000 2894450 
100 50.0000 3851429 
125 62.5000 4799518 
150 75.0000 5751594 
 
CONCLUSION 
The developed method is stability indicating and can be used for 
assessing the stability of azathioprine bulk drugs and 
pharmaceutical dosage form. The developed method is specific, 
selective, robust, and rugged and precise. This method can be 
conveniently used for assessing stability assay of selected 
substances and dissolution of tablets containing azathioprine in 
quality control laboratory. The study showed that the drug is 
moderately degraded in acid (7.5%), base (4.78%) heat (7.46%) 
conditions but highly degraded in the UV (7.93%). 
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